A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
| City: |
|
Alpena |
| State: |
|
Michigan |
| Zip Code: |
|
49707 |
| Conditions: |
|
Type 2 Diabetes Mellitus |
| Purpose: |
|
This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to
determine the effect of ranolazine when added to glimepiride on glycemic control in subjects
with type 2 diabetes mellitus who are inadequately controlled despite current treatment with
stable sulfonylurea or metformin therapy in addition to diet and exercise.
|
| Study Summary: |
|
This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to
determine the effect of ranolazine when added to glimepiride on glycemic control in subjects
with type 2 diabetes mellitus (T2DM) who are inadequately controlled despite current
treatment with stable sulfonylurea or metformin therapy in addition to diet and exercise.
The study has been designed to determine the effect of ranolazine on glycemic control and to
characterize the relationship between HbA1c reduction and other glycemic parameters in
subjects with T2DM.
|
| Criteria: |
|
Inclusion Criteria:
- Written informed consent
- Males and females, 18 to 75 years old, inclusive
- Documented history of T2DM
- Receiving one of the following sulfonylurea (SU) or metformin therapies in addition
to diet and exercise for at least 90 days prior to Screening:
- glimepiride at a daily dose of ≥ 2 mg and ≤ 4 mg
- glimepiride at a daily dose of ≥ 1 mg and ≤ 2 mg for subjects with severe renal
impairment (eGFR < 30 mL/min/1.73m2 by the MDRD method)
- glipizide, glyburide, or glibenclamide (or equivalent) at a daily dose of ≥ 7.5
mg
- gliclazide at a daily dose of > 160 mg (or > 60 mg for the MR formulation)
- metformin at a daily dose of ≥ 1500 mg
- Body mass index (BMI) 27 kg/m2 to 45 kg/m2, inclusive, at Screening
- HbA1c 7% to 10%, inclusive, at Screening and at the end of Period 1 (Day 14 + 2 days)
- FSG ≥ 130 mg/dL (7.2 mmol/L) and ≤ 240 mg/dL (13.3 mmol/L) at Screening and at the
end of Period 1 (Day 14 +2 days)
- C-peptide > 1 ng/mL at Screening
Exclusion Criteria:
- History of type 1 diabetes mellitus
- History of acute or chronic ketoacidosis, ketosis-prone diabetes, or hyperosmolar
hyperglycemic coma
- History of a severe episode of hypoglycemia (eg, requiring assistance of another
person or active intervention of any kind) < 3 months prior to Screening
- Any clinically significant cardiovascular or cerebrovascular event (eg, MI, ACS,
recent revascularization [including coronary artery bypass graft procedures or
percutaneous coronary intervention], transient ischemic attack, or ischemic stroke) ≤
3 months prior to Screening
- Inadequately controlled or unstable hypertension as defined by a systolic blood
pressure (SBP) > 160 mmHg or diastolic blood pressure (DBP) > 100 mmHg at Screening
and at Period 2 Day 1
- Prolonged QTc interval > 500 msec by ECG at Screening, a personal or family history
of QTc prolongation, congenital long QT syndrome, or subjects who are receiving drugs
that prolong the QTc interval, such as Class Ia or Class III antiarrhythmic agents,
erythromycin, and certain antipsychotics (eg, ziprasidone)
- Hemoglobin < 12 g/dL for males or < 11g/dL for females at Screening
- History of bariatric surgery at any time in the past or any other surgery < 2 months
before Screening; or any planned surgery that in the opinion of the investigator
might have an effect on glucose homeostasis
- Any other hospitalization in the 14 days prior to Screening or planned
hospitalization at any time during the study
- Significant weight change (± 5%) < 2 months prior to Screening
- Undergoing any type of dialysis at Screening or planning to undergo any type of
dialysis during the course of the study
- History of liver cirrhosis
- Treatment with strong or moderate CYP3A inhibitors within 14 days prior to Period 2
Day 1
- Treatment with CYP3A inducers or P-gp inducers within 14 days prior to Period 2 Day 1
- Treatment with CYP3A4 substrates with a narrow therapeutic range (eg, cyclosporine,
tacrolimus, or sirolimus) within 14 days prior to Period 2 Day 1
- Treatment with simvastatin at a dose of > 20 mg daily within 14 days prior to Period
2 Day 1
- Use of OHAs other than SU agents or metformin, including but not limited to
dipeptidyl peptidase-4 inhibitors (eg, saxagliptin and sitagliptin) and glucagon-like
peptide-mimetics (eg, exenatide) < 3 months prior to Screening. Use of
thiazolidinediones (TZDs) (eg, rosiglitazone or pioglitazone) < 6 months prior to
Screening
- Weight loss medication or anti-obesity medication (prescription or non prescription)
< 3 months prior to Screening
- Treatment with niacin > 200 mg daily; if receiving > 200 mg daily, should be on
stable doses for ≥ 3 months prior to Screening
- Expected or current treatment with systemic corticosteroids (oral or injectable) for
> 14 days from Screening through the end of Period 2. Topical or inhaled
corticosteroid formulations are permitted at any time during the study.
- If receiving thyroid replacement therapy, should be on stable doses for at least 6
weeks prior to Period 2 Day 1
|
| NCT ID: |
|
NCT01494987 |
| Primary Contact: |
|
Millie Gottwald, PharmD
Phone: +1 (650) 522-5903
Email: mgottwald@gilead.com
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Alpena, Michigan 49707
United States
Diane Campbell
Phone: 989-356-0141
Email: dcampbell@alpenaheartcenter.com
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 25, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|